Bruce E Brockstein
Overview
Explore the profile of Bruce E Brockstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi Z, Wei J, Rifkin A, Wang C, Billings L, Woo J, et al.
Thromb Res
. 2023 Jul;
229:69-72.
PMID: 37419004
Cancer-associated thrombosis (CAT) is common and associated with mortality. We estimated CAT rate by cancer sites and inherited factors among cancer patients from the UK Biobank (N =70,406). The 12-month...
2.
Sullivan K, Kaminer L, Grinblatt D, Campbell N, Nocon C, Harper A, et al.
JCO Oncol Pract
. 2020 Dec;
17(3):153-155.
PMID: 33270522
No abstract available.
3.
Paintal A, Brockstein B
Head Neck Pathol
. 2019 Nov;
14(3):657-665.
PMID: 31721075
To evaluate the performance characteristics of PD-L1 immunohistochemistry (IHC) combined positive scoring (CPS) in core biopsies and aspirate cell blocks from patients with head and neck squamous cell carcinoma (HNSqCCa)....
4.
Ajmani G, Nocon C, Brockstein B, Campbell N, Kelly A, Allison J, et al.
JAMA Otolaryngol Head Neck Surg
. 2018 May;
144(6):483-488.
PMID: 29710108
Importance: A proactive speech and language pathology (SLP) program is an important component of the multidisciplinary care of patients with head and neck squamous cell carcinoma (HNSCC). Swallowing rehabilitation can...
5.
Shah S, Ward J, Bao R, Hall C, Brockstein B, Luke J
Cancer Immunol Res
. 2016 Sep;
4(11):903-909.
PMID: 27638840
Anti-Programed Death 1 (PD-1) is standard immunotherapy for multiple cancers, and the expression of one of its ligands, PD-L1, has been described in germ cell tumors (GCT). Neither the clinical...
6.
Campbell N, Hensing T, Bhayani M, Shaikh A, Brockstein B
Expert Rev Anticancer Ther
. 2016 Jul;
16(8):847-58.
PMID: 27400139
Introduction: As epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of squamous cell carcinomas of the head and neck (SCCHN), several therapeutic agents that target EGFR have been...
7.
Liederbach E, Lewis C, Yao K, Brockstein B, Wang C, Lutfi W, et al.
Ann Surg Oncol
. 2015 Apr;
22(13):4422-31.
PMID: 25893414
Background: This study examined surgical trends for oropharynx squamous cell carcinoma (OPC) from 1998 to 2012, with a post-2009 focus coinciding with the Food and Drug Administration (FDA) approval of...
8.
Cohen E, Karrison T, Kocherginsky M, Mueller J, Egan R, Huang C, et al.
J Clin Oncol
. 2014 Jul;
32(25):2735-43.
PMID: 25049329
Purpose: Induction chemotherapy (IC) before radiotherapy lowers distant failure (DF) rates in locally advanced squamous cell carcinoma of the head and neck (SCCHN). The goal of this phase III trial...
9.
Wali R, Kunte D, De La Cruz M, Tiwari A, Brasky J, Weber C, et al.
PLoS One
. 2012 Jun;
7(6):e38047.
PMID: 22675506
Head and neck squamous cell carcinoma (HNSCC) is a major cause of morbidity and mortality underscoring the need for safe and effective chemopreventive strategies. Targeting epidermal growth factor receptor (EGFR)...
10.
Harshberger C, Harper A, Carro G, Spath W, Hui W, Lawton J, et al.
J Oncol Pract
. 2011 Nov;
7(4):233-7.
PMID: 22043187
Purpose: Computerized physician order entry (CPOE) in electronic health records (EHR) has been recognized as an important tool in optimal health care provision that can reduce errors and improve safety....